Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention

American Journal of Cardiology

Volumn 109, Issue 10, 2012, Pages 1397-1404

  Friedland, Sayuri N ^a   Eisenberg, Mark J ^a   Shimony, Avi ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

BLEEDING; COCHRANE LIBRARY; EMBASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MEDLINE; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SYSTEMATIC REVIEW;

EID: 84860476487     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.01.349     Document Type: Article

References (24)

1. U. Tamhane, P. Meier, S. Chetcuti, K.Y. Chen, S.W. Rha, M.P. Grossman, H. Gurm Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials EuroIntervention 5 2009 384 393
2. I. Singh, N. Shafiq, P. Pandhi, S. Reddy, S. Pattanaik, Y. Sharma, S. Malhotra Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query Br J Clin Pharmacol 68 2009 4 13
3. G.G.L. Biondi-Zoccai, M. Lotrionte, M. Anselmino, C. Moretti, P. Agostoni, L. Testa, A. Abbate, J. Cosgrave, A. Laudito, G.P. Trevi, I. Sheiban Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention Am Heart J 155 2008 1081 1089
4. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
5. J. Higgins, S. Green Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions 2008 Wiley-Blackwell Chichester, England
6. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
7. D.H. Kim, J.Y. Kim, S.W. Moon, J.H. Jung, H.S. Yang, J.H. Cho, M.H. Jeong Effects of long-term triple anti-platelet therapy with low-dose cilostazol after drug-eluting stent implantation Korean J Med 74 2008 368 375
8. Y. Han, Y. Li, S. Wang, Q. Jing, Z. Wang, D. Wang, Q. Shu, X. Tang Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J 157 2009 733 739
9. D.S. Kum, M.H. Kim, J.H. Paik, L.H. Yu, J. Han, K.H. Kim, T.H. Park, K.S. Cha, Y.D. Kim, M.L. Quan, J.Y. Han Clinical effects of additional cilostazol administration after drug-eluting stent insertion Korean Circ J 2009 21 25
10. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, C.W. Lee, M.K. Hong, H.S. Kim, J.K. Ko, J.H. Park, J.H. Lee, S.W. Choi, I.W. Seong, Y.H. Cho, N.H. Lee, J.H. Kim, K.J. Chun, S.J. Park DECLARE-Long Study Investigators Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial) Am J Cardiol 100 2007 1103 1108
11. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, C.W. Lee, M.K. Hong, H.S. Kim, J.K. Ko, J.H. Park, J.H. Lee, S.W. Choi, I.W. Seong, Y.H. Cho, N.H. Lee, J.H. Kim, K.J. Chun, S.J. Park Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients) J Am Coll Cardiol 51 2008 1181 1187
12. S.W. Lee, K.J. Chun, S.W. Park, H.S. Kim, Y.H. Kim, S.C. Yun, W.J. Kim, J.Y. Lee, D.W. Park, C.W. Lee, M.K. Hong, K.S. Rhee, J.K. Chae, J.K. Ko, J.H. Park, J.H. Lee, S.W. Choi, J.O. Jeong, I.W. Seong, S. Jon, Y.H. Cho, N.H. Lee, J.H. Kim, S.J. Park Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG trials) Am J Cardiol 105 2010 168 173
13. C.M. Ahn, S.J. Hong, J.H. Park, J.S. Kim, D.S. Lim Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up Heart Vessels 97 2011 1425 1432
14. Y.D. Chen, Y.L. Lu, Z.N. Jin, F. Yuan, S.Z. Lü A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent Chin Med J Engl 119 2006 360 366
15. J.S. Douglas Jr, D.R. Holmes Jr, D.J. Kereiakes, C.L. Grines, E. Block, Z.M. Ghazzal, D.C. Morris, H. Liberman, K. Parker, C. Jurkovitz, N. Murrah, J. Foster, P. Hyde, G.B. Mancini, W.S. Weintraub Cilostazol for Restenosis Trial (CREST) Investigators Coronary stent restenosis in patients treated with cilostazol Circulation 112 2005 2826 2832
16. J.Y. Kim, K. Lee, M. Shin, M. Ahn, H. Choe, B.S. Yoo, J. Yoon, K.H. Choe, S.H. Lee Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention Circ J 71 2007 1867 1872
17. J.W. Suh, S.P. Lee, K.W. Park, H.Y. Lee, H.J. Kang, B.K. Koo, Y.S. Cho, T.J. Youn, I.H. Chae, D.J. Choi, S.W. Rha, J.H. Bae, T.G. Kwon, J.W. Bae, M.C. Cho, H.S. Kim Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CIlostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 2011 280 289
18. Y.L. Lu, Y.D. Chen, S.Z. Lü [Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention] Zhonghua Xin Xue Guan Bing Za Zhi 35 2007 793 796
19. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, C.W. Lee, S.J. Kang, S.J. Park, J.H. Lee, S.W. Choi, I.W. Seong, N.H. Lee, Y.H. Cho, W.Y. Shin, S.J. Lee, S.W. Lee, M.S. Hyon, D.W. Bang, Y.J. Choi, H.S. Kim, B.K. Lee, K. Lee, H.K. Park, C.B. Park, S.G. Lee, M.K. Kim, K.H. Park, W.J. Park DECLARE-LONG II Study Investigators A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial J Am Coll Cardiol 2011 57 2011 1264 1270
20. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, R. Peto, R. Collins, L.S. Liu COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
21. G.D. Dangas, B.E. Claessen, A. Caixeta, E.A. Sanidas, G.S. Mintz, R. Mehran In-stent restenosis in the drug-eluting stent era J Am Coll Cardiol 56 2010 1897 1907
22. Z. Zhang, J.K. Foster, P. Kolm, C.T. Jurkovitz, K.M. Parker, N.V. Murrah, G.T. Anderson, J.S. Douglas, W.S. Weintraub Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the cilostazol for restenosis (CREST) trial Am Heart J 152 2006 770 776
23. S.-J. Hwang, Y.-H. Jeong, I.-S. Kim, J.-S. Koh, M.-K. Kang, Y. Park, C.H. Kwak, J.-Y. Hwang The cytochrome 2C19 (*)2 and (*)3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention Thromb Res 127 2011 23 28
24. H.G. Xie Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects Clin Pharmacol Ther 62 1997 691 692